 |
PDBsum entry 6jsf
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Structure-Based design of selective β-Site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors: targeting the flap to gain selectivity over bace2.
|
 |
|
Authors
|
 |
K.Fujimoto,
E.Matsuoka,
N.Asada,
G.Tadano,
T.Yamamoto,
K.Nakahara,
K.Fuchino,
H.Ito,
N.Kanegawa,
D.Moechars,
H.J.M.Gijsen,
K.I.Kusakabe.
|
 |
|
Ref.
|
 |
J Med Chem, 2019,
62,
5080-5095.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
BACE1 inhibitors hold potential as agents in disease-modifying treatment for
Alzheimer's disease. BACE2 cleaves the melanocyte protein PMEL in pigment cells
of the skin and eye, generating melanin pigments. This role of BACE2 implies
that nonselective and chronic inhibition of BACE1 may cause side effects derived
from BACE2. Herein, we describe the discovery of potent and selective BACE1
inhibitors using structure-based drug design. We targeted the flap region, where
the shape and flexibility differ between these enzymes. Analysis of the
cocrystal structures of an initial lead 8 prompted us to incorporate spirocycles
followed by its fine-tuning, culminating in highly selective compounds 21 and
22. The structures of 22 bound to BACE1 and BACE2 revealed that a relatively
high energetic penalty in the flap of the 22-bound BACE2 structure may cause a
loss in BACE2 potency, thereby leading to its high selectivity. These findings
and insights should contribute to responding to the challenges in exploring
selective BACE1 inhibitors.
|
 |
|
|
|
|
 |